Sotalol hydrochloride approved for treatment of ventricular arrhythmias, maintenance of normal sinus rhythm

Arbor Pharmaceuticals announced that the FDA has approved a new drug application for sotalol hydrochloride oral solution for the treatment of documented life-threatening ventricular arrhythmias and the maintenance of normal sinus rhythm in patients with a history of highly symptomatic atrial fibrillation or flutter.

Prior to new approval of the oral solution (Sotylize), the drug was only available in tablet form. The tablet form is commonly compounded by pharmacists into a liquid suspension using simple syrup for pediatric and elderly patients who cannot swallow pills, according to a press release.

“Sotylize will plan an important role in facilitating how this important drug is administered to patients with serious cardiac conditions,” Laurence Downey, MD, VP of Medical and Scientific Affairs at Arbor Pharmaceuticals, stated in the release.

The company will launch Sotylize in the first quarter of 2015, according to the release.

Source: www.healio.com